Wuxi Biologics (Cayman)'s total assets for Q2 2025 were ¥60.44B, an increase of 6.07% from the previous quarter. WXIBF total liabilities were ¥11.37B for the fiscal quarter, a -1.11% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.